77. Growth hormone secreting pituitary adenoma Disease details / Clinical trials / Drug dev / DR info
Clinical trial : 1 / Drug : 1 - (DrugBank : 1) / Drug target genes : 2 - Drug target pathways : 20
Growth hormone secreting pituitary adenoma and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
ID | Diseases (Sorted by score) | Score |
---|---|---|
77 | Growth hormone secreting pituitary adenoma | - |
81 | Congenital adrenal hyperplasia | 2.000 |
206 | Fragile X syndrome | 2.000 |
225 | Congenital nephrogenic diabetes insipidus | 2.000 |
233 | Wolfram syndrome | 2.000 |
301 | Macular dystrophy | 2.000 |
13 | Multiple sclerosis/Neuromyelitis optica | 2.000 |
6 | Parkinson disease | 2.000 |
299 | Cystic fibrosis | 2.000 |
2 | Amyotrophic lateral sclerosis | 2.000 |
75 | Cushing disease | 2.000 |
46 | Malignant rheumatoid arthritis | 2.000 |
49 | Systemic lupus erythematosus | 2.000 |
60 | Aplastic anemia | 2.000 |
65 | Primary immunodeficiency | 2.000 |
67 | Polycystic kidney disease | 2.000 |
86 | Pulmonary arterial hypertension | 2.000 |
127 | Frontotemporal lobar degeneration | 2.000 |
158 | Tuberous sclerosis | 2.000 |
285 | Fanconi anemia | 2.000 |
8 | Huntington disease | 2.000 |
113 | Muscular dystrophy | 2.000 |
265 | Lipodystrophy | 2.000 |
97 | Ulcerative colitis | 2.000 |